Abstract: Light arrays for use in systems for separating and irradiating blood are disclosed. In accordance with the present invention, the light array has one or more bulbs with electrical connecting leads and first and second support members connected to the bulbs. The second support member preferably includes a connector for receiving the electrical leads. The support members preferably define an end surface and an interior surface, wherein the support members are disposed adjacent the bulbs so the end surfaces are opposed to define a channel, providing a space where tubing carrying blood or other fluids can be disposed without interfering with the array. The bulbs are most preferably attached to the support members using flexible self-locking straps, and in embodiments using two or more bulbs, the bulbs are also preferably held together by one or more straps. Improved mounting systems for connecting the array to the instrument by one or more spring mounts are also disclosed.
Type:
Grant
Filed:
December 14, 1993
Date of Patent:
October 29, 1996
Assignee:
Therakos, Inc
Inventors:
Kyu H. Lee, Livingston B. Morris, David W. Palmer, deceased
Abstract: A labeled carbamazepine analogue is described comprising:(A) a label, of the type used in immunoassays, having an amine or sulfhydryl group such as horseradish peroxidase;(B) a carbamazepine nucleus; and(C) a linking chain linking the carboxamide group of the carbamazepine nucleus to the label, said linking chain having about 4 to about 40 atoms consisting of:(1) C.sub.2 to C.sub.6 alkylene groups; and(2) 5 to 7 membered heterocyclic ring groups, each group being joined into the linking group through chemical groups selected from(a) esters,(b) amides(c) heteroatoms selected from --O--, --S--, and --NR--; wherein R represents hydrogen or C.sub.1 to C.sub.6 alkyl; and(d) carbonyl.The new labeled analogues are useful in immunoassay elements and processes for detection of carbamazepine drugs, for example, in body fluids.
Type:
Grant
Filed:
August 7, 1992
Date of Patent:
August 6, 1996
Assignee:
Johnson & Johnson Clinical Diagnostics, Inc.
Inventors:
Barbara A. Brummond, Mohan S. Saini, Ignazio S. Ponticello
Abstract: A method for increasing the hematocrit of a normal mammal using erythropoietin (EPO) is provided. The method comprises the steps of administering to the mammal a hematocrit increasing effective amount of EPO, in a pharmaceutically acceptable form. Additionally administered is an effective amount of iron, in a pharmaceutically acceptable form, sufficient to increase the serum iron content of the mammal to an erythropoiesis supportable level. The method is useful for increasing the amount of blood that can be donated for transfusion purposes, in particular autologous transfusion.
Type:
Grant
Filed:
September 19, 1989
Date of Patent:
July 30, 1996
Assignee:
Ortho Pharmaceutical Corporation
Inventors:
John F. A. Vance, Robert I. Abels, Freedolph D. Anderson, William L. Harris, Dorothy Thompson
Abstract: Glioma-derived growth factor is purified from the culture media used to maintain mammalian glioma cells. The protein stimulates mitogenesis of mammalian vascular endothelial cells and is useful for the promotion of vascular development and repair. This unique growth factor is also useful in the promotion of tissue repair.
Type:
Grant
Filed:
March 2, 1994
Date of Patent:
July 2, 1996
Assignee:
Merck & Co., Inc.
Inventors:
Marvin L. Bayne, Kenneth A. Thomas, Jr., Gregory L. Conn
Abstract: Weakly basic ethylenically unsaturated polymerizable monomers and polymers have been prepared. The monomers are represented by the structure (I): ##STR1## wherein R is hydrogen or methyl, and R.sup.1 is alkylene of 1 to 3 carbon atoms. The resulting polymers are water-soluble and cationic at acidic pH, but water-insoluble and neutral in charge at basic pH. The polymers are useful for precipitating nucleic acids.
Type:
Grant
Filed:
May 5, 1995
Date of Patent:
June 4, 1996
Assignee:
Johnson & Johnson Clinical Diagnostics, Inc.
Inventors:
Ignazio S. Ponticello, Jerome C. Swartz, Tobias E. Ekeze
Abstract: A novel prostaglandin receptor has been identified and DNA encoding the receptor has been isolated, purified, sequenced and expressed in host cells. This DNA encoding the novel prostaglandin receptor and host cells expressing the receptor are used to identify modulators of the prostaglandin receptor.
Type:
Grant
Filed:
October 6, 1993
Date of Patent:
May 14, 1996
Assignee:
Merck Frosst Canada Inc.
Inventors:
Mark Abramovitz, Yves Boie, Richard Grygorczyk, Kathleen Metters, Thomas H. Rushmore, Deborah M. Slipetz
Abstract: Mutant human acidic fibroblast growth factor proteins are recombinantly produced having replaced cysteine residues with amino acids incapable of disulfide bond formation. The recombinantly produced mutant human acidic fibroblast growth factor proteins have improved biological activity in the absence of heparin when compared to wild-type recombinant human acidic fibroblast growth factor.
Abstract: Acidic fibroblast growth factor (aFGF) is isolated and purified from human brain tissue. The distinctive and complete amino acid sequences of both bovine and human aFGFs are determined and herein disclosed. Unique genes coding for these disclosed amino acid sequences are constructed. The bovine gene is derived from reverse translation of the aFGF amino acid sequence with unique restriction sites included while the human gene is derived by specific point mutations of the bovine gene. Each gene construct is inserted into an expression vector which is used to transform an appropriate host. The transformed host cells produce recombinant aFGF (r-aFGF), human or bovine, which is purified and has activity equivalent to the native protein. Both recombinant and purified brain-derived human and bovine aFGF are active mitogens for mesoderm and neuroectoderm-derived cells in culture, and promote wound healing of soft tissue, cartilaginous tissue and musculo-skeletal tissue.
Type:
Grant
Filed:
September 25, 1992
Date of Patent:
March 28, 1995
Assignee:
Merck & Co., Inc.
Inventors:
David L. Linemeyer, Linda J. Kelly, Guillermo Gimenez-Gallego, Kenneth A. Thomas, Jr.
Abstract: Monospecific antibodies are produced which are specific for fragments of the connective tissue protein aggrecan, generated by specific stromelysin cleavage. These monospecific antibodies are used in an assay system to detect polypeptide fragments of aggrecan, produced by the specific cleavage of aggrecan by stromelysin. The presence of aggrecan polypeptide fragments demonstrates stromelysin activity. Elevations of stromelysin occur in osteoarthritis, rheumatoid arthritis, atherosclerotic lesions, gout, inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF), certain cancers, joint injuries, and numerous inflammatory diseases. The monospecific antibodies and the assay system are used to quantitate aggrecan polypeptide fragments as a readout of stromelysin activity and to evaluate potential stromelysin inhibitors.
Type:
Grant
Filed:
September 30, 1992
Date of Patent:
February 7, 1995
Assignee:
Merck & Co., Inc.
Inventors:
Richard A. Mumford, Michael W. Lark, Ellen B. K. Bayne, Lori A. Hoerrner
Abstract: Medicinal compositions containing fibroblast growth factor are stabilized against loss of biological activity by including in said composition a stabilizing amount of phytic add, phosvitin, phosphate buffer, (NH.sub.4).sub.6 P.sub.4 O.sub.13, Na.sub.5 P.sub.3 O.sub.10, Na.sub.4 P.sub.2 O.sub.7 and Na.sub.3 P.sub.3 O.sub.9, adenosine tetra, tri, di and mono phosphate and related diadenosine compounds plus other single and multi-phosphorylated mono and di-nucleotides, poly-aspartic acid, poly-adenylic-guanylic add and related compounds, double stranded deoxyribonucleic add, single stranded deoxyfibonucleic acid and poly-glutamic acid. Medicinal compositions for topical use are combined with a viscous excipient such as a water soluble polysaccharide with said combination with a second stabilizier.
Type:
Grant
Filed:
April 1, 1992
Date of Patent:
September 20, 1994
Assignee:
Merck & Co., Inc.
Inventors:
C. Russell Middaugh, Pei-Kuo Tsai, David B. Volkin
Abstract: Glioma-derived growth factor is purified from the culture media used to maintain mammalian glioma cells. The protein stimulates mitogenesis of mammalian vascular endothelial cells and is useful for the promotion of vascular development and repair. This unique growth factor is also useful in the promotion of tissue repair.
Type:
Grant
Filed:
May 27, 1992
Date of Patent:
August 16, 1994
Assignee:
Merck & Co., Inc.
Inventors:
Marvin L. Bayne, Kenneth A. Thomas, Jr., Gregory L. Conn
Abstract: An important intermediate for preparing cephalosporin antibiotics, 7-aminodesacetoxy cephalosporanic acid (7-ADCA), is prepared by a novel bioprocess in which a transformed Penicillium chrysogenum strain is cultured in the presence of an adipate feedstock to produce adipoyl-6-APA (6-amino penicillanic acid); and the in situ expression of an expandase gene, e.g., from Streptomyces clavuligerus, with which the P. chrysogenum has been transformed, converts the adipoly-6-APA by ring expansion to adipoyl-7-ADCA. The final product, 7-ADCA, is then prepared by cleavage of the adipoyl side chain using an adipoyl acylase. The entire synthesis, accordingly, is carried out using bioprocesses, and is efficient and economical.
Type:
Grant
Filed:
August 28, 1992
Date of Patent:
June 7, 1994
Assignee:
Merck & Co., Inc.
Inventors:
Michael J. Conder, Phyllis C. McAda, John A. Rambosek
Abstract: Mutant human acidic fibroblast growth factor proteins are recombinantly produced having replaced cysteine residues with amino acids incapable of disulfide bond formation. The recombinantly produced mutant human acidic fibroblast growth factor proteins have improved biological activity in the absence of heparin when compared to wild-type recombinant human acidic fibroblast growth factor.
Abstract: The entire hepatitis B virus pre-S antigen gene linked in one contiguous reading frame to the hepatitus B virus surface antigen gene has been expressed in Saccharomyces cerevisiae. The expressed protein aggregates into a particulate form which displays the major antigenic sites encoded by both domains, thereby highlighting the utility of yeast as a host for the expression of pre-S domains. This protein is useful in in vitro diagnostic systems and as a vaccine for the treatment and prevention of hepatitis B virus-induced diseases and/or infections.
Type:
Grant
Filed:
June 29, 1987
Date of Patent:
July 28, 1992
Assignee:
Merck & Co., Inc.
Inventors:
Ronald W. Ellis, Peter J. Kniskern, Hagopian Arpi